Long-term safety study of teplizumab in early-stage type 1 diabetes
Observes long-term safety of teplizumab in people with early-stage type 1 diabetes.
Key facts
- Who runs it
- Sanofi
- Where
- Ann Arbor, Aurora, Austin, Baltimore, Bartlett, Buffalo, Chapel Hill, Chicago, Cincinnati, Cleveland, Columbus, Dallas, Farmington Hills, Fort Worth, Gainesville, Grand Rapids, Houston, Indianapolis, Jacksonville, Kansas City, Los Angeles, Louisville, Manhasset, Miami, Morgantown, Nashville, New Haven, Philadelphia, Rochester, Salt Lake City, San Francisco, Staten Island, Syracuse, and Tampa, United StatesSee the 37 sites
- Trial code
- NCT06481904
- U1111-1306-6690
- Registry title
- Registry for Stage 2 Type 1 Diabetes
- Status
- Recruiting
- People taking part
- 200 people, planned
- Started
- 27 Sept 2024
- Expected to end
- 15 Jan 2037
- Type of study
- Observational, 2 groups
- Treatments tested
- TZIELD (teplizumab-mzwv)
- Record updated
- 13 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people in the US with Stage 2 type 1 diabetes. Some will be treated with TZIELD and some will not.
- Sex
- All sexes can join.
- Disease stage
- Stage 2 type 1 diabetes.
- Earlier treatment
- For the TZIELD group: treatment planned, or started within 6 months before joining. The other group is not treated with TZIELD.
Main reasons for not taking part
- Started TZIELD more than 6 months before joining
- Took part in a previous clinical trial for TZIELD
- In an ongoing trial of an investigational product, or ended it within 6 months before joining
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- TZIELD-Exposed Cohort
- Patients in the US diagnosed with Stage 2 T1D who are planned to initiate TZIELD treatment according to the currently approved label or who have initiated TZIELD treatment within 6 months prior to enrollment:
- Day 1: 65 mcg/m2
- Day 2: 125 mcg/m2
- Day 3: 250 mcg/m2
- Day 4: 500 mcg/m2
- Days 5 through 14: 1,030 mcg/m2 per day
- Cumulative dose is approximately 11,240 mcg/m2
- Appropriate written informed consent/assent as applicable for the age of the patient; TZIELD-Unexposed Cohort
- Patients in the US diagnosed with Stage 2 T1D but who are not treated with TZIELD
- Appropriate written informed consent/assent as applicable for the age of the patient
Who cannot take part
- Patients who initiated TZIELD treatment more than 6 months prior to enrollment
- Patients who had participated in a previous clinical trial for TZIELD
- Patients in an ongoing clinical trial of an investigational product or who had ended participation within 6 months prior to study enrollment; patients participating in other observational studies may be enrolled; The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
Where in United States
- University of Michigan Health System - Ann Arbor- Site Number : 8400028Ann Arbor, United StatesTaking people
- University of Colorado Hospital- Site Number : 8400026Aurora, United StatesTaking people
- Texas Diabetes & Endocrinology - Austin - North Mopac Expressway- Site Number : 8400040Austin, United StatesTaking people
- Johns Hopkins School of Medicine- Site Number : 8400031Baltimore, United StatesTaking people
- AM Diabetes & Endocrinology Center- Site Number : 8400012Bartlett, United StatesTaking people
- Women & Children's Hospital of Buffalo- Site Number : 8400018Buffalo, United StatesTaking people
- UNC Children's Hospital- Site Number : 8400008Chapel Hill, United StatesTaking people
- University of Chicago Medical Center- Site Number : 8400017Chicago, United StatesTaking people
- Cincinnati Children's Hospital Medical Center- Site Number : 8400024Cincinnati, United StatesTaking people
- Rainbow Babies And Children's Hospital- Site Number : 8400011Cleveland, United StatesTaking people
- Midtown Medical Center - Columbus- Site Number : 8400013Columbus, United StatesTaking people
- The Ohio State University- Site Number : 8400032Columbus, United StatesTaking people
- University of Texas - Southwestern Medical Center- Site Number : 8400003Dallas, United StatesTaking people
- Farmington Hills, MichiganHospital not named in the registryTaking people
- Fort Worth, TexasHospital not named in the registryTaking people
- University of Florida Health- Site Number : 8400035Gainesville, United StatesTaking people
- Corewell Health - Grand Rapids - Michigan Street Northeast- Site Number : 8400009Grand Rapids, United StatesTaking people
- Texas Children's Hospital- Site Number : 8400002Houston, United StatesTaking people
- Indiana University Health Riley Hospital for Children- Site Number : 8400004Indianapolis, United StatesTaking people
- Nemours Children's Speciality Care- Jacksonville- Site Number : 8400006Jacksonville, United StatesTaking people
- Children's Mercy Adelle Hall Campus- Site Number : 8400014Kansas City, United StatesTaking people
- University of California Los Angeles Health- Site Number : 8400020Los Angeles, United StatesTaking people
- Norton Brownsboro Hospital- Site Number : 8400030Louisville, United StatesTaking people
- Feinstein Institute for Medical Research (Northwell)- Site Number : 8400016Manhasset, United StatesTaking people
- Nicklaus Children's Hospital - Miami - Southwest 62nd Avenue- Site Number : 8400034Miami, United StatesTaking people
- University of Miami Miller School of Medicine- Site Number : 8400037Miami, United StatesTaking people
- Morgantown, West VirginiaHospital not named in the registryTaking people
- Vanderbilt University Medical Center- Site Number : 8400023Nashville, United StatesTaking people
- Yale University School of Medicine- Site Number : 8400025New Haven, United StatesTaking people
- Hospital of The University of Pennsylvania- Site Number : 8400021Philadelphia, United StatesTaking people
- The Children's Hospital of Philadelphia- Site Number : 8400029Philadelphia, United StatesTaking people
- Mayo Clinic- Site Number : 8400010Rochester, United StatesTaking people
- University of Utah Health Hospital- Site Number : 8400019Salt Lake City, United StatesTaking people
- University of California San Francisco - Mission Bay- Site Number : 8400005San Francisco, United StatesTaking people
- Ten's Medical PC- Site Number : 8400027Staten Island, United StatesTaking people
- SUNY Upstate Medical University - Syracuse- Site Number : 8400007Syracuse, United StatesTaking people
- University of South Florida- Site Number : 8400022Tampa, United StatesTaking people
About the trial
What the trial wants to find out
Stage 2 Type 1 Diabates (T1D) is an early stage of T1D characterized by dysglycemia but not yet leading to clinical symptoms. Progression of the disease to Stage 3 (clinical T1D), leads to overt hyperglycemia requiring eventually exogenous insulin.
Read full original descriptionShow less
TZIELD® (teplizumab-mzwv) has been approved to delay onset of stage 3 T1D, by the United States (US) Food and Drug Administration (FDA) for adults and children aged 8 years and older with Stage 2 T1D.
The purpose of this study is to collect general information on patients with stage 2 T1D and further information on the long-term effects of TZIELD® in patients with Stage 2 T1D, treated as per standard of care.
The 2 groups in the trial
- TZIELD group
Patients prior to the initiation of TZIELD treatment or initiated TZIELD treatment within 6 months to study enrollment
Treatment: TZIELD (teplizumab-mzwv)
- Comparator group
Patients not planned to be treated
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Observational, Long-term Safety Study of TZIELD® (Teplizumab-mzwv) in Patients With Stage 2 Type 1 Diabetes
- Plain-language title
- Long-term safety study of teplizumab in early-stage type 1 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 13 April 2026